Everolimus resistance in clear cell renal cell carcinoma: miRNA-101 and HIF-2 alpha as molecular triggers?

• Tipo: Artigo em Revista Científica Internacional
• Data: 2019

Autores

Nogueira, I (Autor) Outra; Dias, F (Autor) Outra; Morais, M (Autor) Outra; Teixeira, AL (Autor) Outra; Rui Medeiros (Autor) ICBAS

Revista

Título: Future Oncology

Vol. 15

Páginas: 2361-2370

ISSN: 1479-6694

Editora: Future Medicine Ltd.

Indexação

ISI Web of Knowledge - 10 Citações

Scopus - 10 Citações

Outras Informações

ID Authenticus: P-00Q-XKK

DOI: 10.2217/fon-2019-0067

Abstract (EN): Aim: The majority of clear cell renal cell carcinoma patients develop resistance to mTOR inhibitors. Materials & methods: As an in vitro model four cell lines were used: HKC-8, 786- O, RCC-FG-2 and an everolimus-resistant cell line (786-OR) established during this study. The quantification of miRNA-101 and HIF-2 alpha mRNA levels was assessed by real-time PCR. Results: We observed a significant decrease of miRNA-101 intracellular levels in 786-OR. However, this miRNA presented higher extracellular levels. Additionally, we found a significant increase of HIF-2 alpha in 786-OR. Conclusion: The circulating levels of miRNA-101 may be a potential biomarker of anti-mTOR therapy response and resistance prediction. Moreover, the resistance to mTOR inhibitors seems to be related with the overexpression of HIF-2 alpha.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 10